肿瘤药学2018，Vol.8Issue(2)：236-239,4.DOI:10.3969/j.issn.2095-1264.2018.02.25
高危妊娠合并卵巢癌患者应用米非司酮联合贝伐珠单抗的疗效分析
Efficacy of Mifepristone Combined with Bevacizumab on High-Risk Pregnant Patients with Ovarian Cancer
摘要
Abstract
Objective To study the efficacy of mifepristone and bevacizumab in patients with high-risk pregnancy combined with ovar-ian cancer. Methods 60 patients with high risk pregnancy complicated with ovarian cancer who were treated in our hospital between Janu-ary 2012 and January 2017 were selected as the subjects. They were divided into study group (n=30) and control group (n=30). The patients in study group were terminated by mifepristone combined with bevacizumab and the patients in control group were terminated by routine abortion assisted with conventional anticancer drugs. After treatment, the bleeding volume during labor, bleeding in different time periods (compared with postpartum menstrual volume), and postoperative physical condition (postoperative drug side effects and complications of patients) were compared between the two groups. Results The bleeding volume and related indexes of patients in the study group were sig-nificantly better than those in the control group (P<0.05). The bleeding volume of patients in the study group was significantly lower than that in the control group (P<0.05) at different time after operation. The side effects and complications of patients in the study group were significantly better than in the control group (P<0.05). Conclusion Mifepristone combined with bevacizumab can effectively reduce the high risk labor, blood loss, incidence of side effects and complications of pregnant patients with ovarian cancer after surgery.关键词
米非司酮/高危妊娠/卵巢癌/贝伐珠单抗/产后出血Key words
Mifepristone/High-risk pregnancy/Ovarian cancer/Bevacizumab/Postpartum hemorrhage分类
医药卫生引用本文复制引用
张爱红,段元兰,黄亚岚,李翔..高危妊娠合并卵巢癌患者应用米非司酮联合贝伐珠单抗的疗效分析[J].肿瘤药学,2018,8(2):236-239,4.基金项目
国家自然科学基金项目(30970298). （30970298）
